Navigation Links
Silence Therapeutics Signs Collaboration with miRagen Therapeutics to Evaluate Delivery of Novel microRNA-based Therapeutics
Date:1/9/2012

LONDON, January 9, 2012 /PRNewswire/ --

- Third collaboration to investigate the potential application of Silence's proprietary RNAi delivery technologies in the development of novel microRNA-based therapeutics

Silence Therapeutics plc (AIM: SLN) ("Silence"), a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with miRagen Therapeutics, Inc. ("miRagen"), to assess the delivery potential of Silence's proprietary DBTC delivery system with miRagen's novel microRNA- (miRNA-) based therapeutics. MiRagen is a pre-clinical stage biopharmaceutical company founded to develop innovative miRNA-based therapeutics for the treatment of cardiovascular and muscle disease.

Under the terms of the agreement, miRagen will provide Silence with specific miRNA sequences, which Silence will formulate with its proprietary DBTC delivery system in order to develop multiple candidate drugs. MiRagen will undertake in vitro and in vivo studies of the candidate drugs developed under the agreement and select lead candidates for further evaluation. Financial terms of the collaboration are not disclosed.

DBTC is a proprietary RNAi delivery system developed by Silence. It is a novel lipid-based formulation that functionally delivers short interfering RNA (siRNA) to liver endothelial cells, hepatocytes and other liver cell types with high efficiency.


SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Silence Therapeutics Signs siRNA Delivery Collaboration With Top 10 Pharma Company
2. Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases
3. Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
4. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
5. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
6. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
7. Silence Therapeutics Provides Year-end Update
8. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
9. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
10. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
11. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... and BOSTON , January 23, 2015 ... discovery and development company, is delighted to announce that the ... awarded to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
(Date:1/22/2015)... WOODBRIDGE, ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics ... company with a focus on Omega-3 therapies for cardiovascular disease ... summary of the Company,s accomplishments in 2014 and its outlook ... Dear Fellow Shareholders, We would like ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... in Carotid Atherosclerosis, LEXINGTON, Mass., Oct. 24 ... its pivotal clinical trial (PROVIDENCE-1),studying the effect of ... peripheral arterial disease (PAD) will be,presented on November ... late breaker,Scientific Session at the American Heart Association,s ...
... Today the National Legal and Policy,Center (NLPC) asked ... for,International Development (USAID) to investigate the possibility that ... groups operating,needle exchange programs for drug users in ... activist George,Soros are recipients of these legally questionable ...
Cached Medicine Technology:ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting 2ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting 3Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups 2
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the ... created for kids with cancer. The Chemo Duck App, available on ... with enjoyable games to help children of all ages living with ... to keep kids entertained, educated and at ease while waiting for ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... ... be covered by medical insurance will be provided by Khanna institute in Beverly Hills ... (Vocus) April 13, 2010 -- ... for eye and sight problems, hereby announces that it is offering its Beverly Hills patients ...
... contaminated water, and their health effects, will be the ... Superfund Research Program during the next five years. The ... that the Superfund Research Program, funded since 1989, will ... 2015 to conduct the research. Four environmental projects ...
... A research project of the Neuroscience Center of the ... sustaining memory traces of visual stimuli in the human ... memory is associated with synchronisation of neurons, which facilitates ... basis of interaction between the brain areas, it was ...
... ... that 80% of Women Enjoy Reading or Viewing Pornography; 73% Wish They Were Having More Sex. ... San Francisco, CA (PRWEB) April 13, ... had a copy of What Women Really Want in Bed: The Surprising Secrets Women Wish ...
... lowered stroke risk, but only if they didn,t smoke, study ... indulge in moderate drinking, you,ve probably heard that it might ... new British study supports that notion, but it also finds ... apply to smokers. , "Any potential beneficial effect of drinking ...
... Autism in ... concern with no known cure. The causes of autism are hotly debated, but a new ... ... of children who have received this stem cell treatment for autism , a group of ...
Cached Medicine News:Health News:Khanna Institute to Provide Intacs Corneal Implants in Beverly Hills 2Health News:Khanna Institute to Provide Intacs Corneal Implants in Beverly Hills 3Health News:University of Arizona Superfund Research Program receives $14 million 2Health News:Human working memory is based on dynamic interaction networks in the brain 2Health News:'What Women Really Want In Bed' Is A Man's Guide To Giving Her The Sex She Wants 2Health News:'What Women Really Want In Bed' Is A Man's Guide To Giving Her The Sex She Wants 3Health News:'What Women Really Want In Bed' Is A Man's Guide To Giving Her The Sex She Wants 4Health News:Smoking May Erase Heart Benefits of Light Drinking 2Health News:Smoking May Erase Heart Benefits of Light Drinking 3Health News:Thanks to a New Stem Cell Therapy, a 9-year Old Autistic Boy Talks to his Father for the First Time 2Health News:Thanks to a New Stem Cell Therapy, a 9-year Old Autistic Boy Talks to his Father for the First Time 3Health News:Thanks to a New Stem Cell Therapy, a 9-year Old Autistic Boy Talks to his Father for the First Time 4
... TME 227 T is a ... temporary cardiac pacing and monitoring ... The TME 227 T features ... myocardium, which allows safe and ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: